Daniel Vorobiof

7.1k total citations
61 papers, 1.6k citations indexed

About

Daniel Vorobiof is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Daniel Vorobiof has authored 61 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Daniel Vorobiof's work include Cancer Treatment and Pharmacology (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Daniel Vorobiof is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Daniel Vorobiof collaborates with scholars based in South Africa, Switzerland and United States. Daniel Vorobiof's co-authors include Geoffrey Falkson, L. Goedhals, Adina Alberts, Gabriel Vorobiof, C.A. van der Merwe, Freddy Sitas, Bernardo L. Rapoport, Miguel Martín, Carla I. Falkson and Michele Ghielmini and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Daniel Vorobiof

59 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Vorobiof South Africa 18 938 390 340 300 163 61 1.6k
Ellen R. Gaynor United States 22 751 0.8× 292 0.7× 554 1.6× 324 1.1× 192 1.2× 42 1.6k
H. Curé France 22 1.2k 1.3× 327 0.8× 410 1.2× 742 2.5× 81 0.5× 82 2.0k
F J Cummings United States 20 691 0.7× 159 0.4× 215 0.6× 300 1.0× 140 0.9× 35 1.2k
Mary Cianfrocca United States 14 869 0.9× 239 0.6× 279 0.8× 533 1.8× 67 0.4× 31 1.3k
Catherine Shannon Australia 20 704 0.8× 286 0.7× 183 0.5× 285 0.9× 107 0.7× 48 1.2k
Wen-Qi Jiang China 27 1.3k 1.4× 390 1.0× 804 2.4× 295 1.0× 155 1.0× 76 2.1k
Naveen Faridi Pakistan 24 570 0.6× 265 0.7× 311 0.9× 345 1.1× 42 0.3× 85 1.4k
Massimo Lopez Italy 21 1.6k 1.7× 598 1.5× 213 0.6× 516 1.7× 88 0.5× 59 2.2k
Thomas Makatsoris Greece 22 1.0k 1.1× 338 0.9× 135 0.4× 198 0.7× 85 0.5× 85 1.5k
J J Costanzi United States 20 641 0.7× 283 0.7× 162 0.5× 272 0.9× 158 1.0× 36 1.2k

Countries citing papers authored by Daniel Vorobiof

Since Specialization
Citations

This map shows the geographic impact of Daniel Vorobiof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Vorobiof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Vorobiof more than expected).

Fields of papers citing papers by Daniel Vorobiof

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Vorobiof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Vorobiof. The network helps show where Daniel Vorobiof may publish in the future.

Co-authorship network of co-authors of Daniel Vorobiof

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Vorobiof. A scholar is included among the top collaborators of Daniel Vorobiof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Vorobiof. Daniel Vorobiof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Golan, Talia, Ofer Purim, Danny Rosin, et al.. (2024). Multi-institutional validation survey on Belong.life's conversational artificial intelligence (AI) oncology mentor, "Dave.. Journal of Clinical Oncology. 42(16_suppl). e13596–e13596. 1 indexed citations
2.
Moccia, Alden A., Christian Taverna, Sämi Schär, et al.. (2020). Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Advances. 4(23). 5951–5957. 17 indexed citations
3.
Rapoport, Bernardo L., Annette J. Theron, Daniel Vorobiof, et al.. (2020). Prognostic Significance of the Neutrophil/Lymphocyte Ratio in Patients undergoing Treatment with Nivolumab for Recurrent Non-Small-Cell Lung Cancer. PubMed. 9(3). LMT37–LMT37. 8 indexed citations
4.
Vorobiof, Daniel, et al.. (2015). Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report. Journal of Medical Case Reports. 9(1). 158–158. 2 indexed citations
5.
Rordorf, Tamara, Ibrahim A. Hassan, Hamdy A. Azim, et al.. (2014). Bone health in breast cancer patients: A comprehensive statement by CECOG/SAKK Intergroup. The Breast. 23(5). 511–525. 14 indexed citations
6.
Tabane, Keo & Daniel Vorobiof. (2011). Bone Targeted Therapies in Early Breast Cancer. Current Treatment Options in Oncology. 12(4). 412–423. 4 indexed citations
7.
Martinelli, Giovanni, Shu-Fang Hsu Schmitz, Thomas Cerny, et al.. (2010). Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. Journal of Clinical Oncology. 28(29). 4480–4484. 168 indexed citations
8.
9.
Rapoport, Bernardo L., et al.. (2009). Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer. International Journal of Gynecological Cancer. 19(6). 1137–1141. 21 indexed citations
10.
Vorobiof, Daniel, et al.. (2009). Malignant Pleural Mesothelioma: Medical Treatment Update. Clinical Lung Cancer. 10(2). 112–117. 13 indexed citations
11.
Eniu, Alexandru, Robert W. Carlson, Nagi S. El Saghir, et al.. (2008). Guideline implementation for breast healthcare in low- and middle-Income countries: Treatment resource allocation. Cancer. 113(S8). 2269–2281. 75 indexed citations
12.
Olver, I. N., Michael Byrne, Euan Walpole, et al.. (2007). Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. European Journal of Cancer. 43(12). 1829–1832. 13 indexed citations
13.
14.
Abratt, Raymond P., Neil W. White, & Daniel Vorobiof. (2005). Epidemiology of mesothelioma—a South African perspective. Lung Cancer. 49. S13–S15. 7 indexed citations
15.
Vorobiof, Gabriel, et al.. (2003). Primary Osteosarcoma of the Breast: A Case Report. The Breast Journal. 9(3). 231–233. 19 indexed citations
16.
Vorobiof, Daniel, et al.. (2002). Malignant pleural mesothelioma: a phase II trial with docetaxel. Annals of Oncology. 13(3). 412–415. 22 indexed citations
17.
Vorobiof, Daniel, Ulrich R. Kleeberg, R. Pérez-Carrión, et al.. (1999). A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer. Annals of Oncology. 10(10). 1219–1225. 16 indexed citations
18.
Ruff, Paul, W. Paska, L. Goedhals, et al.. (1994). Ondansetron Compared with Granisetron in the Prophylaxis of Cisplatin-lnduced Acute Emesis: A Multicentre Double-Blind, Randomised, Parallel-Group Study. Oncology. 51(1). 113–118. 90 indexed citations
19.
Vorobiof, Daniel & W. R. Bezwoda. (1994). A randomised trial of vindesine plus interferon-α2b compared with interferon-α2b or vindesine alone in the treatment of advanced malignant melanoma. European Journal of Cancer. 30(6). 797–800. 11 indexed citations
20.
Vorobiof, Daniel, et al.. (1988). Cyclophosphamide, Mitoxantrone, Vincristine and Prednisone in the Treatment of Non-Hodgkin’s Lymphoma. Oncology. 45(5). 378–379. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen R. Gaynor Breakdown of academic impact, for papers by H. Curé Breakdown of academic impact, for papers by F J Cummings Breakdown of academic impact, for papers by Mary Cianfrocca Breakdown of academic impact, for papers by Catherine Shannon Breakdown of academic impact, for papers by Wen-Qi Jiang Breakdown of academic impact, for papers by Naveen Faridi Breakdown of academic impact, for papers by Massimo Lopez Breakdown of academic impact, for papers by Thomas Makatsoris Breakdown of academic impact, for papers by J J Costanzi
Rankless by CCL
2026